CDK1 and acute lymphoblastic leukemia: Finally, to explore the feasibility of CD2066 application for chemotherapy-free drug combinations, we evaluated its effects in association with the inhibition of CDK1, recently found hyperactivated in T-ALL and, therefore, indicated as an appealing pharmacological target [74,75].